SENS.L

Sensyne Health
Sensyne Health PLC - Update on General Meeting
8th February 2022, 09:34
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 0204B
Sensyne Health PLC
08 February 2022
 

      

 

Sensyne Health plc


("Sensyne" or the "Company")

 

Update on General Meeting

 

Confirmed cases of COVID-19 mean that General Meeting will be held as a closed meeting

 

Oxford, U.K. 8 February 2022: Sensyne Health plc (LSE:SENS) today announces that due to a number of confirmed COVID-19 cases, the Company's General Meeting to be held at 2.00 p.m. on Friday, 11 February 2022 (the "General Meeting") will now be held as a closed meeting, with the minimum number of members legally required to be present to form a quorum in accordance with the Company's articles of association. Shareholders will not be permitted to attend in person and are therefore advised not to travel to the General Meeting. The Company is taking these precautionary measures to safeguard its shareholders', stakeholders' and employees' health and make the General Meeting as safe and efficient as possible.

 

Shareholders are encouraged to submit their votes by proxy in advance and to appoint the Chair of the meeting as their proxy (rather than their own choice of person), with voting instructions, to ensure their vote is counted. Completed forms of proxy must be returned so as to be received by the Company's Registrars, Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA by no later than 2.00 p.m. on 9 February 2022, as set out in the Notice of General Meeting contained within the Circular sent to shareholders on 26 January 2022. The Circular is available from the Company's website at https://www.sensynehealth.com/investors/shareholder-information. Shareholders' attention is again drawn to the importance of voting at the General Meeting.

 

A video link for virtual attendance is being made available to provide shareholders with the opportunity to listen to the General Meeting and to have their questions answered. If you would like to join the video conference, please contact CSCSensynehealth@consilium-comms.com by close of business on Wednesday, 9 February 2022.

 

 

 

-ENDS-

Notes for editors:

About Sensyne Health: https://www.sensynehealth.com/

Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model - a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems.  The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers remote patient monitoring and real-time decision-making systems for healthcare organisations and their patients. In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

 

Contact details:

Sensyne Health


 

Lord (Paul) Drayson PhD FREng, Chief Executive Officer

Dr Richard Pye, Chief Financial Officer

+44 (0) 330 058 1845

 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+ 44 (0) 20 7418 8900

 

Dr Christopher Golden

James Steel

 


 

Liberum (Joint Broker)


Phil Walker

William Hall

+ 44 (0) 20 3100 2000

Consilium Strategic Communications


Mary-Jane Elliott

Jessica Hodgson

CSCSensynehealth@consilium-comms.com

+44 (0) 7780 600290

SternIR


Julie Seidel

Julie.seidel@sternir.com

 +1 (212) 362 1200

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOGFIFVAFLITIIF ]]>
TwitterFacebookLinkedIn